Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion’s FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways—Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management’s sentiment? Real-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data—already summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines—ideal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
Artivion insider James Mackin has filed a notice to sell 30,921 shares of common stock of AORT through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,430,714.67. These shares relate to an option originally granted on 03/05/2019 and acquired on 12/02/2025, with the purchase price paid in cash.
Artivion had 47,374,939 shares of common stock outstanding at the time referenced. Over the prior three months, Mackin sold 17,580 shares of common stock on 11/10/2025 for gross proceeds of $784,400.26 and 34,210 shares on 11/13/2025 for gross proceeds of $1,568,812.44. By signing the notice, he represents that he does not know of any undisclosed material adverse information about the company’s current or prospective operations.
Artivion, Inc. (AORT)11/21/2025. He exercised options to buy 20,301 shares of common stock at $18.44 per share and another 27,075 shares at $11.03 per share. On the same date, he sold blocks of 14,586 shares at a weighted average price of $44.919, 5,715 shares at $45.346, 18,705 shares at $44.91, and 8,370 shares at $45.345, with each price representing a weighted average within disclosed ranges. After these transactions, he directly owned 44,753 shares of Artivion common stock.
Artivion, Inc. (AORT) senior vice president of Clinical & MD Affairs Marshall Stanton reported insider transactions in company stock. On 11/20/2025, he sold 11,888 shares of common stock at a weighted average price of $44.14 per share, and in separate transactions sold additional shares at weighted average prices of $44.315 and $44.278 per share. The sales were reported as open-market dispositions.
On the same date, Stanton exercised stock options to buy 2,033 shares at an exercise price of $18.44 per share and 1,355 shares at an exercise price of $11.03 per share, then sold the corresponding shares. Following these transactions, he reported beneficial ownership of 44,753 shares of Artivion common stock held directly, along with vested and unexercised stock options covering 20,301 shares at $18.44 and 27,075 shares at $11.03.
A holder of AORT common stock, Marshall S. Stanton, has filed a Form 144 notice to sell 47,376 shares of common stock through Fidelity Brokerage Services on the NYSE. The issuer has 47,374,939 common shares outstanding, which shows the planned sale is small relative to the total share count.
The shares to be sold were acquired on 11/21/2025 through the exercise of two stock options originally granted on 02/23/2022 and 11/08/2022, paid for in cash. The form also reports recent sales by Stanton over the past three months, including 15,276 shares sold on 11/20/2025 for gross proceeds of $674,833.49.
Marshall S. Stanton has filed a Rule 144 notice to sell 15,276 shares of AORT common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of
The shares to be sold were recently acquired through a mix of restricted stock vesting and option exercises, including blocks of 3,917, 3,986, and 3,985 shares from restricted stock and 2,033 and 1,355 shares from options granted in
Over the past three months, Stanton has also sold 2,566 and 4,993 AORT common shares for gross proceeds of
Artivion, Inc. (AORT) director share sale disclosed
A director of Artivion, Inc. reported selling 4,200 shares of the company’s common stock on 11/18/2025 at a weighted average price of $45.098 per share, with individual sale prices ranging from $44.89 to $45.295. After this transaction, the director beneficially owns 27,189 shares directly. The price range disclosure indicates multiple trades were executed to complete the total sale.
The notice reports a planned sale of 4,200 shares of common stock of AORT by a holder under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $189,413.28 and an approximate sale date of 11/18/2025. These shares were acquired as restricted stock from the issuer on 06/06/2024, with no separate cash payment described. As context, the filing states that 47,374,939 shares of the issuer’s common stock were outstanding at the time referenced.
Artivion, Inc. (AORT) senior vice president and general counsel Jean F. Holloway reported option exercises and related stock sales in November 2025. On November 14, 2025, she exercised options to acquire 6,393 shares of common stock at $29.62 per share and sold 6,393 shares at $45.00 per share, leaving 169,801 shares owned directly, then 163,408 shares after the sale. On November 17, 2025, she exercised options for 6,394 shares at $29.62 and sold 6,394 shares at $45.17, with 169,802 shares shown after the exercise and 163,408 shares directly owned after the sale.
The derivative table shows these transactions came from stock options granted with a $29.62 exercise price and an expiration date of March 5, 2026. The filing notes that the option exercises and subsequent sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options vested in equal annual installments beginning March 5, 2020.
Artivion, Inc. (AORT) reported insider share transactions by its Chief Commercial Officer on Form 4. On November 14, 2025 and November 17, 2025, the officer exercised stock options to acquire 6,393 and 6,394 shares of common stock, respectively, at an exercise price of $29.62 per share. On the same dates, the officer sold the same numbers of shares at prices of $44.67 and $45.17 per share. After these transactions, the officer directly owned 198,842 shares of Artivion common stock. The filing notes that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options originally began vesting on March 5, 2020.
Artivion, Inc. (AORT) reported an insider stock sale by a senior officer. On 11/17/2025, the company’s VP and Chief Accounting Officer sold 6,000 shares of common stock in an open market transaction at a weighted average price of $45.73 per share, with trade prices ranging from $45.605 to $45.91. After this transaction, the officer beneficially owns 135,380 shares of Artivion common stock, held directly. The filing notes that detailed price breakdowns for each trade within the reported range are available upon request.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
